GUIDE — Guiding an Improved Dementia Experience — is the new dementia care model from the CMS and the CMMI (Centers for Medicare and Medicaid Innovation) for beneficiaries covered by traditional fee-for-service (FFS) Medicare and their caregivers. It represents an incremental step forward in managing neurodegenerative diseases effectively.
Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Bluebird Bio gene therapy Skysona has won FDA approval, making it the first FDA-approved therapy for cerebral adrenoleukodystrophy, an ultra-rare and fatal neurological disorder. Skysona’s regulatory green light follows the August approval of Zynteglo, a Bluebird gene therapy for a rare blood disorder.
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
Startup PAQ Therapeutics is developing drugs that work like Pac-Man, gobbling up components of a cell associated with disease. The biotech has closed $30 million in financing to continue its research, with a neurodegenerative disorder as its lead disease target.
The company has a "unique" approach to treating Alzheimer's, CEO Arnon Rosenthal says - taking an immunotherapy approach to neurodegenerative disease.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Aquinnah's approach targets a protein called TDP-43 that has been found to accumulate in patients with neurodegenerative conditions like ALS, Alzheimer's disease and certain dementias.
Cambridge startup Amylyx just raised $1.9 million in equity and grants for its combination drug that mediates stress in mitochondria and the endoplasmic reticulum.
Immunotherapy startup Alector just raised $32 million to expand its pipeline of immune system-modulating drugs for neurodegenerative disease. The "hypothesis-driven" company has a bold approach to this family of disease, which has few effective therapies.
Neuro Vigor, a startup based in Indiana, has a new theory for what causes multiple sclerosis — and has found a generic hypertension drug that could potentially be repurposed to treat an array of neurodegenerative diseases.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Cambridge-based NeuroPhage is developing, well, a better way to clear the trash. It’s chasing Alzheimer’s, Parkinson’s and other aging-related degenerative diseases with a technology that breaks up disease-causing plaques in the brain. The company just tacked on another $10 million to its existing Series D private equity financing, bringing that total round to $27 million. To date, NeuroPhage has […]